Open an account

Alnylam Pharmaceuticals

ALNY · NASDAQ

$230.71−$2.58 (−1.11%)TodayMarket closed ·
Prev close $233.29

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Employees
2,500
Headquarters
Cambridge, Massachusetts
Listed
May 28, 2004
Sector
Health Care
Industry
Biotechnology
Website
alnylam.com

ALNY key statistics

Market cap
31.22B
Price-earnings ratio
39.27
Dividend yield
—
Average volume
1.24M
Volume
1.04M
Open price
$237.73
High today
$238.96
Low today
$229.54
52 Week high
$495.55
52 Week low
$197.81

Alnylam Pharmaceuticals (ALNY) at a glance

As of Oct 20, 2026, Alnylam Pharmaceuticals (ALNY) shares are priced at $230.71, giving the company a market cap of 31.22B and a price-to-earnings ratio of 39.27.

Today the stock has traded between $229.54 and $238.96. The current price is 0.5% above the day's low and 3.5% below its high.

Volume so far is 1.04M shares, in line with the average of 1.24M shares a day.

Over the past year Alnylam Pharmaceuticals has ranged from $197.81 to $495.55, and now sits 11% of the way up that range.

Alnylam Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $1.21 per share against an estimate of $1.59.

The average analyst price target is $378.84, 64.2% above the current price, from 23 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 23 analyst ratings say Buy
  • Buy82.6%
  • Hold17.4%
  • Sell0.0%
Price target · 30 analystsAvg $378.84
Low
$238.36
Now
$230.71
High
$594.30

ALNY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 64.6% on average.

  1. Q3 FY24: reported -$0.87 per share against an estimate of -$0.9063
  2. Q4 FY24: reported -$0.65 per share against an estimate of -$0.636
  3. Q1 FY25: reported -$0.44 per share against an estimate of -$1.03
  4. Q2 FY25: reported -$0.51 per share against an estimate of -$0.7349
  5. Q3 FY25: reported $2.11 per share against an estimate of $0.7613
  6. Q4 FY25: reported $0.82 per share against an estimate of $1.15
  7. Q1 FY26: reported $1.51 per share against an estimate of $0.9815
  8. Q2 FY26: reported $1.21 per share against an estimate of $1.59

ALNY news

  • Press releaseBusiness Wire

    Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

  • Piero Cingari

    Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

  • Press releaseGlobe Newswire

    Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releaseGlobe Newswire

    Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Press releaseGlobe Newswire

    Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Piero Cingari

    Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%

  • Press releaseBusiness Wire

    AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

  • Press releaseBusiness Wire

    Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Similar companies

Companies in the same industry as Alnylam Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.